Skip to main
ARDX

Ardelyx (ARDX) Stock Forecast & Price Target

Ardelyx (ARDX) Analyst Ratings

Based on 9 analyst ratings
Strong Buy
Strong Buy 56%
Buy 44%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Ardelyx Inc has demonstrated a positive outlook due to its strategic investments in the ArdelyxAssist patient assistance program and its salesforce, which are expected to enhance prescription volumes and patient engagement, particularly for the XPHOZAH product. Financial projections are favorable, with revenue estimates for IBSRELA anticipated to reach $422 million in FY26 and $878 million in FY29, reflecting growth potential that exceeds consensus expectations. Additionally, clinical data indicates effective treatment outcomes for patients with severe constipation, further supporting the efficacy of Ardelyx's therapeutic offerings.

Bears say

Ardelyx Inc. is experiencing declining gross-to-net (GTN) margins for its product Ibsrela, which fell to 31% in Q3 2025 from 32.2% in Q2 2025, indicating potential pricing pressures and diminishing profitability. Despite the reported efficacy of Xphozah in reducing serum phosphate levels, the company faces threats from potential changes to reimbursement pricing structures that could adversely affect sales. Furthermore, the ambitious peak net sales guidance of over $1 billion for Ibsrela appears unrealistic given current market conditions, compounded by the risk of failing to secure crucial product labels that could restrict market traction.

Ardelyx (ARDX) has been analyzed by 9 analysts, with a consensus rating of Strong Buy. 56% of analysts recommend a Strong Buy, 44% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Ardelyx and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Ardelyx (ARDX) Forecast

Analysts have given Ardelyx (ARDX) a Strong Buy based on their latest research and market trends.

According to 9 analysts, Ardelyx (ARDX) has a Strong Buy consensus rating as of Feb 4, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $13.78, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $13.78, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Ardelyx (ARDX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.